MOMA Therapeutics Completes $150 Million Series B Financing

MOMA Therapeutics is an American molecular machine drug discovery platform developer dedicated to the development of next-generation precision medicines by targeting molecular machines for human diseases. MOMA has not announced any developable targets, but has disclosed that it modulates cystic fibrosis (CF) The concept of research and development of transporter drugs has further announced its therapeutic potential. Recently completed a $150 million Series B financing. The funds obtained from this round of financing will be used to advance a number of precision oncology R&D projects into the clinic.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.